# AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

> **NCT06068153** · PHASE2 · WITHDRAWN · sponsor: **ETOP IBCSG Partners Foundation**

## Conditions studied

- Metastatic Non Small Cell Lung Cancer
- KRAS G12C

## Interventions

- **DRUG:** Sotorasib
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06068153
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-03
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** In view of the recent developments in the field (the increasing number of trials with new KRAS inhibitors), the window of opportunity to answer the question raised in the AMBER trial was missed.
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068153, "AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06068153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*